Last update 21 Nov 2024

Oritinib Mesylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
甲磺酸瑞厄替尼
+ [1]
Mechanism
EGFR T790M inhibitors(EGFR T790M inhibitors), EGFR exon 19 deletion inhibitors, EGFR exon 21 L858R mutation inhibitors
Inactive Organization-
Drug Highest PhaseApproved
RegulationSpecial Review Project (CN)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
EGFR positive non-small cell lung cancer
CN
09 Sep 2024
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma
CN
11 Jun 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Lung Non-Small Cell CarcinomaPhase 1
CN
24 Mar 2021
EGFR positive non-small cell lung cancerPreclinical-31 Jan 2020
EGFR-mutated non-small Cell Lung CancerPreclinical
CN
11 Jul 2019
Advanced Malignant Solid NeoplasmPreclinical
CN
13 Sep 2018
Advanced Lung Non-Small Cell CarcinomaPreclinical
CN
25 Apr 2018
metastatic non-small cell lung cancerDiscovery-31 Jan 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
245
Rilertinib 200 mg
(cheuhavjff) = saynashiur khkmukwent (nsrnusisjs, 15.2 - 22.3)
Positive
08 Sep 2024
Gefitinib 250 mg
(cheuhavjff) = knxwfcitdv khkmukwent (nsrnusisjs, 7.1 - 12.6)
Phase 3
227
(kpqsdwextl) = sdvztxijpv rvmngxeikg (pgypltktwr )
Met
Positive
17 Jun 2024
吉非替尼
(kpqsdwextl) = iwmkyhzgpt rvmngxeikg (pgypltktwr )
Met
Phase 2
286
(dose verification study)
(hzqpjvxlyl) = vwqyweaeuo nwmxspjikn (dabfdjidiq, 42.4 - 68.8)
Positive
04 Jul 2022
(second-line registration study)
(hzqpjvxlyl) = aygllbsrie nwmxspjikn (dabfdjidiq, 53.7 - 66.8)
Phase 2
227
(jtcsqhouhr) = pmiszfmrrk zakdmumrif (wehkkwectq, 42.4% - 68.8%)
-
30 Mar 2022
Phase 1
20
(uvbvcegyxh) = 3 patients at 300 or 400mg dose, all of DLTs were increased blood creatine phosphokinase osskpwlsij (hcviqggmgy )
Positive
25 Sep 2021
Phase 1
20
(fsvpgqpwhx) = javflnioog psdhkipmym (vrcxuuoaxn, 19.12 - 63.95)
-
25 Sep 2021
(fsvpgqpwhx) = ykmsjhxnhx psdhkipmym (vrcxuuoaxn, 19.12 - 63.95)
Phase 1
60
(dsjlxnfses) = fkpaodzkio fhgbfrivps (xuytrebqtl, 48.2 - 73.8)
Positive
08 Sep 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free